Citizens National Bank Trust Department Raises Stock Position in Pfizer Inc. $PFE

Citizens National Bank Trust Department raised its holdings in Pfizer Inc. (NYSE:PFE) by 0.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 46,103 shares of the biopharmaceutical company’s stock after acquiring an additional 395 shares during the period. Citizens National Bank Trust Department’s holdings in Pfizer were worth $1,118,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of PFE. Capital Advisory Group Advisory Services LLC raised its holdings in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 388 shares in the last quarter. Trust Co of the South boosted its holdings in Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 441 shares in the last quarter. Charter Oak Capital Management LLC increased its position in Pfizer by 4.3% during the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 444 shares during the period. Ballentine Partners LLC raised its stake in shares of Pfizer by 0.5% during the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock worth $2,260,000 after buying an additional 458 shares in the last quarter. Finally, Members Trust Co lifted its holdings in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 467 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Saturday, September 27th. Finally, Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Price Performance

Shares of NYSE PFE opened at $26.27 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company’s 50-day moving average price is $24.76 and its 200 day moving average price is $24.14. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The stock has a market cap of $149.36 billion, a price-to-earnings ratio of 13.97, a PEG ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business posted $0.60 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.